Skip to main content
CTEV
NYSE Trade & Services

Claritev Q2 Revenue Beats, but Material Weakness and DOJ Probe Linger

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Health Tech Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$32.59
Mkt Cap
$555.587M
52W Low
$11.5
52W High
$74.07
52W Position info
183% above low
Off High info
56% below high
Rel. Volume info
2.2× avg
Market data snapshot near publication time

CTEV has more than doubled off its 52-week low of $11.5 on elevated volume (2.2× avg).

Summary

Claritev's Q2 2026 revenue and adjusted EBITDA beat expectations, but the 10-Q discloses an unremediated material weakness, an ongoing DOJ civil probe, and high client concentration.


Key Events · Earnings and Guidance · CTEV

  • Q2 Revenue and EBITDA Beat

    Revenue rose 6.6% YoY to $257.5M; adjusted EBITDA reached $155.8M, exceeding consensus estimates.

  • Material Weakness Unremediated

    IT general control deficiencies remain unremediated as of June 30, 2026, causing disclosure controls to be ineffective.

  • DOJ Civil Probe Ongoing

    The DOJ closed its criminal antitrust investigation but issued a civil investigative demand on May 19, 2026; the outcome and potential penalties are uncertain.

  • High Client Concentration

    One client accounted for 35% of Q2 2026 revenue, posing a material risk if the relationship is lost.


Analysis · CTEV · Trade & Services

Claritev posted a solid Q2 with revenue up 6.6% to $257.5M and adjusted EBITDA of $155.8M, beating expectations. However, the 10-Q reveals that a previously disclosed material weakness in IT controls remains unremediated, rendering disclosure controls ineffective. The DOJ civil investigation is ongoing, and the company disclosed that one client represents 35% of revenue — a significant concentration risk. Two executives also adopted 10b5-1 trading plans, signaling potential future insider sales.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, CTEV was trading at $32.59 on NYSE in the Trade & Services sector, with a market capitalization of approximately $555.6M. The 52-week trading range was $11.50 to $74.07. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

CTEV - Latest Insights

CTEV
Nov 12, 2026, 4:30 PM EST
Filing Type: 4
Importance Score:
7
Price at Filing: $27.37
Real-time Price: $22.57 info
Change: -$4.80 (-18%) info
Market Cap: $385.335M info
CTEV
Nov 09, 2026, 10:48 AM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $23.86
Real-time Price: $22.57 info
Change: -$1.29 (-5%) info
Market Cap: $385.335M info
CTEV
Nov 09, 2026, 6:05 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $22.71
Real-time Price: $22.57 info
Change: -$0.1425 (-0.63%) info
Market Cap: $385.335M info
CTEV
Nov 09, 2026, 6:01 AM EST
Source: Reuters
Importance Score:
8
Price at Filing: $22.71
Real-time Price: $22.57 info
Change: -$0.1425 (-0.63%) info
Market Cap: $385.335M info
CTEV
Aug 07, 2026, 6:00 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $26.84
Real-time Price: $22.57 info
Change: -$4.27 (-16%) info
Market Cap: $385.335M info